JANESVILLE, Wis., June 6, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals. SHINE has provided the first supply of Ilumira – its non-carrier added lutetium-177 (n.c.a. Lu-177) chloride – to Blue Earth Therapeutics that will be used in clinical trials to assess a potential treatment for men with prostate cancer. This partnership follows SHINE's submission of a Drug Master File to the U.S. Food and Drug Administration – enabling SHINE to be on a fast track to deliver for its customers.
JANESVILLE, Wis., March 19, 2024 /PRNewswire/ -- SHINE Technologies, a next-generation fusion company, announced Greg Piefer, founder and CEO, and Ross Radel, CTO, will present at energy conferences this week: the Fusion Industry Association (FIA) Annual Conference in Washington, D.C., and the CERAWeek Innovation Agora in Houston, Texas.
JANESVILLE, Wis., March 18, 2024 /PRNewswire/ -- SHINE Technologies, a leader in medical isotope production, will showcase its innovative capabilities for producing non-carrier-added lutetium-177 (n.c.a Lu-177), a radioisotope used in targeted cancer treatments, at the 7th Theranostic World Congress (TWC), March 22-24 in Santiago, Chile. Attendees are invited to visit Booth A13 to learn about SHINE's production capabilities at its Cassiopeia facility.
JANESVILLE, Wis. and SYDNEY, Sept. 19, 2022 /PRNewswire/ -- SHINE Technologies, a next-generation fusion technology company, and Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced that they have entered into a clinical supply agreement. SHINE will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177).
SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced the company has submitted a Drug Master File (DMF)...
SHINE Technologies, a next-generation nuclear technology company, and Telix Pharmaceuticals, a biopharmaceutical company headquartered in Australia, have signed a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu), a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation (MTR) investigational products.
JANESVILLE, Wis.--(BUSINESS WIRE)--SHINE Medical Technologies LLC today announced the appointments of Jean Rogers, Ph.D., an environmental, social and governance (ESG) expert, and Tamanna Bembenek, Ph.D., a global marketing leader, to the company’s board of directors.